Investigational Medicine Venetoclax (ABT-199) Receives Breakthrough Therapy Designation In Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL) In Previously Treated Patients With The 17p Deletion Genetic Mutation

You are here: